Ken Young
Overview:
I am a clinically-oriented diagnostic physician with clinical expertise in the pathologic diagnosis of hematologic cancers including tumors of the bone marrow, lymphoid tissue, spleen and pre-malignant hematologic conditions. Another area of interest is blood cancer classification with molecular and genetic profiling. In my research program, we focus on molecular mechanisms of tumor progression, cell-of-origin, biomarkers, and novel therapeutic strategies in lymphoma, myeloma and leukemia. In addition to patient care and translational research, medical education and scientific communication are also part of interest. I provide persistent support for the physician-scientist program and Blood Cancer Pathology program in the department and cancer center. Many residents, fellows, graduates and postdocs have worked and been trained in our program. We perform comprehensive clinical and research functions that include bone marrow, lymphoma pathology, clinical flow cytometry, cytogenetics, molecular diagnostics and outside services.
I am currently the director of hematopathology division that provides diagnostic consultation services and relevant specialized testing for patients with various types of acute and chronic leukemia, lymphoma and benign hematologic disorders. I am specialized in the diagnosis of hematological disorders, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, B and T-cell lymphomas, Hodgkin lymphoma, cutaneous and orbital lymphomas and benign bone marrow and lymph node disorders.
Our group has been supported by various funding resources since 2006 and has published 318 original peer-reviewed articles and 56 review articles, many in high- impact journals (Nature Clin Onc Rev, JCO, JAMA, Lancet, Blood, JHO, Leukemia and Clinical Cancer Research). The contributions to the hematology field include the development of novel diagnostic algorithms, molecular and genetic biomarkers for classification of blood cancer, lymphoid neoplasms and lymphoid diseases.
Positions:
Professor of Pathology
Member of the Duke Cancer Institute
Education:
M.D. 1984
Ph.D. 1995
Residency, Pathology
Fellowship, Pathology
Grants:
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
Hematology & Transfusion Medicine (T32)
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
Publications:
Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.
Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.
PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination.
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters-Reply.
Research Areas:
